Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -4.00 -0.48% 836.00 820.00 850.00 845.00 835.00 845.00 434,142 16:35:07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.3 -9.7 -17.3 - 621

Maxcyte Share Discussion Threads

Showing 501 to 524 of 675 messages
Chat Pages: 27  26  25  24  23  22  21  20  19  18  17  16  Older
DateSubjectAuthorDiscuss
05/2/2021
17:58
Some major volume here today. 2 x 2m share buy at 9.85 first thing. Have a good weekend all.
2theduke
05/2/2021
15:42
Highly likely we'll break through £10 next week imo.
someuwin
05/2/2021
12:23
Agreed Acuere. I guess if you're a trader rather than investor though, you might congratulate yourself on what you say above. Personally, I'm here for the long-haul
adamb1978
05/2/2021
11:30
Yes for a while now a UT trade at the end of the day has consistently been higher than any other trade during the day, and it then seems to set the trend for the following day. There is big demand out there. I feel long term holders will be amply rewarded but for those not wanting to stay the trip, I still don’t see the point of selling before Nasdaq listing. There was a poster on Twitter yesterday, who sold early doors, then reported he’d bought back in, at higher price, about an hour later and then sold again before the end of the day and was patting himself on the back for the profit he made. Had he done nothing and sold today he would probably have made twice as much. It just seems obvious, sit tight and let the US institutions try and outbid themselves because they know how much more these will cost once Nasdaq offering happens.
acuere
05/2/2021
09:04
Adam , I agree but also add that whilst low volume - look at the order book, someone has consistently been buying whatever they can from sellers. Albeit to avoid a rns auction it appears.
2theduke
05/2/2021
08:58
For those new to the story here, look at all these diseases that MXCT's tech is currently being used with in ongoing clinical trials. Each of these are being developed by, and funded by some of the biggest and best biotech companies in the world. MXCT calls them partners not customers. MXCT is getting revenues now for licenses, milestones, tech rental, sales etc. But as and when any of these drugs come to market MXCT will get significant royalties on sales. That's the BIG driver here - where else can you get exposure to that sort of upside at such a low price? And that's just the trials being done currently. We know that as they enter 2021 their pipeline of new partnerships is the largest they've ever seen!
someuwin
05/2/2021
08:46
TheTrotsky Agree that with these sort of rises you need to be braced for sharp pullbacks too. However the one thing whic might support it here is the roadshow which supported the recetn placing. That will ahve put MSCT on the radar on a range of US investors, particularly as the company moves to Nasdaq. A bunch of those will realise the revaluation which will occur and will therefore be picking up shares now, partly for arbitrage and partly as a long-term holding in a company which the were previously unaware of. Its crazy when a share price goes up almost the same as your entire in-price in 1 day! Adam
adamb1978
05/2/2021
08:41
One has to hope that there's a number, as yet, unreported trades this morning because the share price has gone up 125p thus far on very thin reported volumes. Not complaining, wish all my shares did this, but, being pragmatic, rises on such thin volumes rarely hold. Defeinitely one to hold, at least to the NASDAQ listing, but could get bumpy between now and then (hope not; not good for the nerves).
thetrotsky
05/2/2021
08:36
Not sure how I misplaced my post from yesterday but clearly this is significantly undervalued following the December cx0001 trial outcomes. Even at current value , the royalties due from just the one partner trial would be £40m a year ? In other words it would make sense for the drug producer to buy mxct at current mcap just to not to have to pay royalities. So you have a current valuation supported almost by one good outcome, then you can add in the 140 other programmes running and the core revenue stream. There is a lot of research out there for those interested, fascinating. Imo etc . Good luck all. I see the us ipo at $1-$1.5 if no further good news arises personally.
2theduke
05/2/2021
08:31
Completely agree Edward - doing nothing is a positive action - I’ll definitely be taking it until nasdaq listing. When you see what’s out there in US they could take this to a 3-5 bil valuation. That’s not a ramp, based on comps and is out of our hands now. Price action to date proves it.
nimbo1
05/2/2021
08:29
this is where you need zen like calm and sit tight. Much deeper pocketed and sector wise investors are waking up to this one. Shame on the Uk fund management community who refuse to open their eyes to new sectors. cashflow today is their mantra. IMO they miss the woods for the trees. They have done so here with very few UK insitutional investors who did the work here.
edwardt
05/2/2021
08:27
Everyone having fun? :)
nimbo1
05/2/2021
08:04
Still not much stock available.
someuwin
04/2/2021
17:51
Well the crispr drug has been given 70 percent chance of success of going commercial by the analysts. That alone underpins market cap here for max imo. Maxcyte have another 100 shots plus on goal. How do you value that?! In the billions imo when on Nasdaq.
nimbo1
04/2/2021
17:29
Likewise, you can expect a valuation a lot higher than where we are today. There is a huge appetite for gene engineering/ cell therapy shares on Nasdaq. For example, look at Sana Biotechnology that has an upcoming IPO. Only 18mth old, clinical/P1 testing at least a year away, and no chance of profits for years if ever. A couple of weeks ago they were hoping to raise $130m with IPO, last week they increased that to $323m (15m shares at $20 to $23), but such is the demand that has now increased to $517m (22m shares at $23-$24). Out of them and Mxct I know which one I prefer.
acuere
04/2/2021
17:27
1. So the gene therapy market could be $50-150bn by 2030 2. Their EP technology appears to feature in over >15% of new gene therapy cell trials started over the past three years ... could they gain a >>30% market share in the long term? 3. If they secure 5% royalties on all future agreements ... We would have a royalty stream of $4bn+ per annum under a VERY blue sky scenario, and $0 if the technology ends up not working. One thing I know for sure. Regret is a very powerful force. NEVER INVEST MORE THAN YOU CAN ACCORD TO LOSE - the chances of failure >>50%!
trickydicky1
04/2/2021
16:50
no idea but my bet is higher.
edwardt
04/2/2021
16:46
Would anyone care to suggest what the share price should be if it had a Nasdaq valuation?
tictac
04/2/2021
14:08
As well as increasing liquidity with the raise yesterday, they also appointed Stifel as joint broker. So I guess all the pieces are in place now to move forward with the NASDAQ application. Hopefully news on that soon. "Modelio Equity ยท Feb 2 On top of all these fundamental triggers, a clear valuation trigger is the listing on NASDAQ USA before November this year. Analyzing peers in the US, there is a clear valuation discount for MaxCyte, which we think will close once on the NASDAQ."
someuwin
04/2/2021
14:03
Don't Adam! I had the opportunity to buy ASOS at less than £1 and thought they were overpriced! Arghh! Actually bought these on a newspaper recommendation at 250p back in June 2018 (can't remember whether it was the Times or Telegraph) for a bit of a dabble without doing much background research. Sometimes you just get lucky.
thetrotsky
04/2/2021
14:00
It's shooting the lights out. A dilutive placing serving only to bolster the balance sheet, suggesting they weren't so comfortable with working capital. I therefore presume the market has got excited about this because apparently savvy investors in life sciences were willing to stump up at 700p yesterday and over-subscribe.
trident5
04/2/2021
13:51
we all do it! i guess my thinking was that i got my original capital back and i can leave the rest to do its thing. it has at least made me sit on my hands on the 75%. lets go to the nasdaq and see what this is really worth.
edwardt
04/2/2021
13:46
edwardt - Yes, I've made that mistake before. I bought BOO at just over 30p and sold too much on the way up, and bought FDEV at about 320p and again sold too much on the way up. I bought MXCT at around 170p and have no intention of completing a hattrick of very expensive mistakes!!! Adam
adamb1978
04/2/2021
13:39
Edward actually it was sensible. It was before the gene editing was really proven in a test case. In dec the sickle cell treatment really showed viability. Since then it’s a invigorated business opportunity. So actually I think you did well taking 25% off only (with hindsight)
2theduke
Chat Pages: 27  26  25  24  23  22  21  20  19  18  17  16  Older
ADVFN Advertorial
Your Recent History
LSE
MXCT
Maxcyte
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210423 04:24:07